insights_auto
Sebab 2X1 menurun 3.91%?
Terokai Dengan Lebih Terperincichevron_right
2X1:ETR
Abivax SA
€78.70
arrow_downward
-3.91%(-3.20) 1H
23 Okt, 5:35:57 PTG GMT+2 · EUR
search
Semua simbol
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk 2X1...
Buka
€80.20
Tinggi
€81.20
Rendah
€78.25
Permodalan Pasaran
6.82B
Purata volum
1.59K
Volum
536.00
tgi 52 mgu
€137.40
rdh 52 mgu
€60.85
EPS
-€5.20
Bilangan pekerja
98
Buka
€80.20
Tinggi
€81.20
Rendah
€78.25
Permodalan Pasaran
6.82B
Purata volum
1.59K
Volum
536.00
tgi 52 mgu
€137.40
rdh 52 mgu
€60.85
EPS
-€5.20
Bilangan pekerja
98
Cerita berita
Daripada sumber web dan rakan kongsi berita
Investing.com UK
·
2 hari lalu
Piper Sandler reiterates Abivax stock rating on trial data By Investing.com
Profil
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Perihal Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Pekerja98
Diasaskan4 Dis 2013
Ibu pejabat-
Sektor-
Laman webabivax.com